Omeros

Novo Nordisk Gets New Complement System Approach to Rare Diseases With Deal for Omeros Drug

Novo Nordisk is paying $240 million up front for global rights to zaltenibart, an Omeros drug that blocks the MASP-3 protein to treat diseases caused by excessive activity of the complement system. This antibody drug is on track for pivotal testing that could show superiority over blockbuster AstraZeneca drugs that are standard treatments for a rare blood disorder.

By Frank Vinluan

Pharma BioPharma,

Oyster Point dry eye drug is approved, but omission in label crimps financing plan

An Oyster Point Pharma drug for dry eye disease has won FDA approval, the first treatment for the condition that comes as a nasal spray. In addition to that drug approval, the FDA on Monday rejected two drugs, one from Omeros and the other from United Therapeutics.

By Frank Vinluan